Provided by Tiger Trade Technology Pte. Ltd.

Islamic Stocks

5,851.79
+76.811.33%
Number of Gainers:10
Number of Losers:6
Number of Flat:1
PE:- -
High:5,878.11
Open:5,778.20
Low:5,778.20
Close:5,774.95
Volume:236.27M
Turnover:65.00B
Market Cap:31.19T
Float Cap:28.90T

Loading ...

Wells Fargo Adjusts Price Target on Microsoft to $725 From $700, Maintains Overweight Rating

MT Newswires Live
·
Oct 01

Morgan Stanley Adjusts Price Target on Apple to $355 From $360, Keeps Overweight Rating

MT Newswires Live
·
Oct 01

Analysts Offer Insights on NA Companies: Factset Research (FDS), Alphabet Class A (GOOGL) and Cigna (CI)

TIPRANKS
·
Oct 01

New Buy Rating for Nvidia (NVDA), the Technology Giant

TIPRANKS
·
Oct 01

Nvidia, Meta Clash With Anthropic as AI Safety Regulation Debate Grows

TIPRANKS
·
Oct 01

Market Chatter: Rogue AI Agents Possibly Linked to OpenAI Targeted US and Canadian Government Websites

MT Newswires Live
·
Oct 01

Global Bond Rout Deepens as US and European Yields Surge, Nasdaq Futures Erase Gains, European Stocks Tumble, Dollar Hits Three-Month High

Deep News
·
Oct 01

Tech Giants' AI Data Center Push Faces Growing Local Backlash Across US

Deep News
·
Oct 01

Microsoft Partner OpenAI Completes Sale of 13% Stake to SoftBank

MT Newswires Live
·
Oct 01

Tesla September Registrations Rise Across Europe, Extending Recovery

Reuters
·
Oct 01

Unilever's Food Exit is no Repeat of Its Ice-Cream Split

Dow Jones
·
Oct 01

Thales - Thales and Google Strengthen Their Partnership to Secure Agent-Based AI

THOMSON REUTERS
·
Oct 01

Tesla New Registrations in Sweden +38.4% Year-on-Year in September, Compiler Mobility Sweden Says

THOMSON REUTERS
·
Oct 01

Piper Sandler Raises Microsoft Price Target to $610, Citing Copilot and E7 as New M365 Monetization Drivers

Deep News
·
Oct 01

Pfizer Says Tilrekimig Hits Phase 2 Atopic Dermatitis Endpoint with 62.5% EASI-75 at Week 16

Reuters
·
Oct 01

Pfizer - no Serious Adverse Events Related to Tilrekimig in Phase 2 Study

THOMSON REUTERS
·
Oct 01

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

THOMSON REUTERS
·
Oct 01

Pfizer - Tilrekimig Well-Tolerated with Teae Rates Comparable to Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - 62.5% of Patients on Tilrekimig 450 Mg Q2w Achieve Easi-75 vs 19.9% Placebo

THOMSON REUTERS
·
Oct 01

Pfizer - Phase 2 Study Meets Primary Endpoint with Significant Easi-75 Improvement at Week 16

THOMSON REUTERS
·
Oct 01